Evidence map›Paper›PMID 40963608›Full record

ArticleFrontiers in immunology2025

Dysregulated tryptophan metabolism: driving T cell subsets and PI3K-Akt pathway alterations in Hashimoto's thyroiditis.

Lijian Zhang, Xinrui Zhou, Tingwei Cheng, Qiong Wang, Xiaoyan Pei, Lei Yu, Guoxi Jin

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. International journal of molecular sciences · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lijian ZhangDepartment of Endocrinology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Xinrui ZhouDepartment of Endocrinology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Tingwei ChengDepartment of Endocrinology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Qiong WangDepartment of Endocrinology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Xiaoyan PeiDepartment of Endocrinology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Lei YuDepartment of Endocrinology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Guoxi JinDepartment of Endocrinology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study explored the role of tryptophan (Trp) metabolism in Hashimoto's thyroiditis (HT) pathogenesis using clinical samples and animal models, given the unclear mechanisms and limited treatments of HT. Methods: Clinically, serum Trp, lactic acid, and alanine levels in 10 HT patients and 10 healthy controls were measured by ELISA. In animal experiments, female C57BL/6 mice were divided into Con, HT, HT+T (Trp supplemented), and HT+I (Trp metabolism inhibitor IDO1/TDO-IN-4 treated) groups. After inducing autoimmune thyroiditis, various tests were conducted, including ELISA for inflammation factors, HE staining for thyroid pathology, flow cytometry for T cell subsets, RNA-seq for gene expression, Western Blotting for PI3K-Akt pathway proteins, and CIBERSORT for immune cell analysis. Results: HT patients had significantly lower serum Trp levels. The HT group showed thyroid damage and increased inflammation factors. Trp supplementation alleviated thyroid damage and reduced inflammation factors, while the inhibitor worsened them. Trp also regulated T cell subsets and immune cell environment. RNA-seq and Western Blotting indicated Trp's impact on immune response and PI3K-Akt pathway. Conclusion: Trp metabolism abnormality is associated with HT. Trp supplementation can alleviate HT progression by regulating T cell function and the PI3K-Akt pathway, while inhibiting Trp metabolism exacerbates it. This suggests Trp metabolism's potential as a therapeutic target for HT.

Indexed as

Hashimoto DiseasePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktT-Lymphocyte SubsetsTryptophanAdultAnimalsDisease Models, AnimalFemaleHumansMiceMice, Inbred C57BLMiddle AgedSignal TransductionPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTryptophanHashimoto’s thyroiditisimmunePI3K-Akt signaling pathwayT cell subsetstryptophan metabolism

Identifiers

PMID40963608
PMCPMC12436296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.